These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

706 related articles for article (PubMed ID: 34731856)

  • 1. Real-World Single-Center Comparison of the Safety and Efficacy of Entecavir, Tenofovir Disoproxil Fumarate, and Tenofovir Alafenamide in Patients with Chronic Hepatitis B.
    Jeong S; Shin HP; Kim HI
    Intervirology; 2022; 65(2):94-103. PubMed ID: 34731856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renal and bone side effects of long-term use of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide fumarate in patients with Hepatitis B: a network meta-analysis.
    Liu Z; Zhao Z; Ma X; Liu S; Xin Y
    BMC Gastroenterol; 2023 Nov; 23(1):384. PubMed ID: 37950196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide in treatment-naive hepatitis B patients.
    Chon HY; Ahn SH; Kim YJ; Yoon JH; Lee JH; Sinn DH; Kim SU
    Hepatol Int; 2021 Dec; 15(6):1328-1336. PubMed ID: 34799838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of switching from tenofovir disoproxil fumarate to tenofovir alafenamide versus entecavir for chronic hepatitis B patients in Greece.
    Sinakos E; Kachru N; Tsoulas C; Jeyakumar S; Smith NJ; Yehoshua A; Cholongitas E
    J Comp Eff Res; 2024 Apr; 13(4):e230090. PubMed ID: 38317634
    [No Abstract]   [Full Text] [Related]  

  • 5. Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B.
    Papatheodoridis GV; Dalekos GN; Idilman R; Sypsa V; Van Boemmel F; Buti M; Calleja JL; Goulis J; Manolakopoulos S; Loglio A; Papatheodoridi M; Gatselis N; Veelken R; Lopez-Gomez M; Hansen BE; Savvidou S; Kourikou A; Vlachogiannakos J; Galanis K; Yurdaydin C; Esteban R; Janssen HLA; Berg T; Lampertico P
    J Hepatol; 2020 Nov; 73(5):1037-1045. PubMed ID: 32553667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of tenofovir alafenamide vs. entecavir on hepatocellular carcinoma risk in patients with chronic hepatitis B.
    Lee HW; Cho YY; Lee H; Lee JS; Kim SU; Park JY; Kim DY; Ahn SH; Kim BK; Park SY
    Hepatol Int; 2021 Oct; 15(5):1083-1092. PubMed ID: 34402025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world single-center experience with entecavir and tenofovir disoproxil fumarate in treatment-naïve and experienced patients with chronic hepatitis B.
    Kim YM; Shin HP; Lee JI; Joo KR; Cha JM; Jeon JW; Yoon JY; Kwak MS
    Saudi J Gastroenterol; 2018; 24(6):326-335. PubMed ID: 30004042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of hepatocellular carcinoma in antiviral treatment-naïve chronic hepatitis B patients treated with entecavir or tenofovir disoproxil fumarate: a network meta-analysis.
    Huang ZH; Lu GY; Qiu LX; Zhong GH; Huang Y; Yao XM; Liu XH; Huang SJ; Wu T; Yuan Q; Wang YB; Su YY; Zhang J; Xia NS
    BMC Cancer; 2022 Mar; 22(1):287. PubMed ID: 35300634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the on-treatment risks for hepatocellular carcinoma between entecavir and tenofovir: A propensity score matching analysis.
    Ha I; Chung JW; Jang ES; Jeong SH; Kim JW
    J Gastroenterol Hepatol; 2020 Oct; 35(10):1774-1781. PubMed ID: 32154938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tenofovir monotherapy versus tenofovir plus entecavir combination therapy in HBeAg-positive chronic hepatitis patients with partial virological response to entecavir.
    Wang YH; Liao J; Zhang DM; Wu DB; Tao YC; Wang ML; Chen EQ; Tang H
    J Med Virol; 2020 Mar; 92(3):302-308. PubMed ID: 31609007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the side effects of antivirals in chronic hepatitis B patients: a single-center experience.
    Gok Sargin Z; Celik U; Dusunceli I; Ustundag Y
    Acta Gastroenterol Belg; 2022; 85(4):587-592. PubMed ID: 36566368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved bone and renal safety in younger tenofovir disoproxil fumarate experienced chronic hepatitis B patients after switching to tenofovir alafenamide or entecavir.
    Da Wang F; Zhou J; Li LQ; Li YJ; Wang ML; Tao YC; Zhang DM; Wang YH; Chen EQ
    Ann Hepatol; 2023; 28(5):101119. PubMed ID: 37271480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-term and long-term safety and efficacy of tenofovir alafenamide, tenofovir disoproxil fumarate and entecavir treatment of acute-on-chronic liver failure associated with hepatitis B.
    Li J; Hu C; Chen Y; Zhang R; Fu S; Zhou M; Gao Z; Fu M; Yan T; Yang Y; Li J; Liu J; Chen T; Zhao Y; He Y
    BMC Infect Dis; 2021 Jun; 21(1):567. PubMed ID: 34126939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of tenofovir alafenamide vs. tenofovir disoproxil fumarate on hepatocellular carcinoma risk in chronic hepatitis B.
    Lee HW; Cho YY; Lee H; Lee JS; Kim SU; Park JY; Kim DY; Ahn SH; Kim BK; Park SY
    J Viral Hepat; 2021 Nov; 28(11):1570-1578. PubMed ID: 34435412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the Efficacy of Tenofovir Versus Tenofovir plus Entecavir in the Treatment of Chronic Hepatitis B in Patients With Poor Efficacy of Entecavir: A Systematic Review and Meta-analysis.
    Chen J; Zhao SS; Liu XX; Huang ZB; Huang Y
    Clin Ther; 2017 Sep; 39(9):1870-1880. PubMed ID: 28797777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicenter study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in South Korea.
    Kim SU; Seo YS; Lee HA; Kim MN; Lee YR; Lee HW; Park JY; Kim DY; Ahn SH; Han KH; Hwang SG; Rim KS; Um SH; Tak WY; Kweon YO; Kim BK; Park SY
    J Hepatol; 2019 Sep; 71(3):456-464. PubMed ID: 30959156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in treatment-naïve chronic hepatitis B.
    Lim J; Choi WM; Shim JH; Lee D; Kim KM; Lim YS; Lee HC; Choi J
    Liver Int; 2022 Jul; 42(7):1517-1527. PubMed ID: 35343041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retreatment Efficacy and Renal Safety of Tenofovir Alafenamide, Entecavir, and Tenofovir Disoproxil Fumarate After Entecavir or Tenofovir Cessation.
    Chiu SM; Chang KC; Hu TH; Hung CH; Wang JH; Lu SN; Chen CH
    Dig Dis Sci; 2023 Feb; 68(2):665-675. PubMed ID: 35976597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Renal Safety of Prophylactic Tenofovir Alafenamide for HBV-Infected Cancer Patients Undergoing Chemotherapy.
    Lee IC; Lan KH; Su CW; Li CP; Chao Y; Lin HC; Hou MC; Huang YH
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tenofovir vs. Entecavir on Outcomes of Hepatitis B Virus-Related Hepatocellular Carcinoma after Radiofrequency Ablation.
    Hu Z; Zeng H; Hou J; Wang J; Xu L; Zhang Y; Chen M; Zhou Z
    Viruses; 2022 Mar; 14(4):. PubMed ID: 35458386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.